Clinical Trial Update: Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia [Phase 1, Phase 2]

View source ↗

Summary

The Phase 1/2 trial of the subcutaneous implant AUR-201 for unilateral microtia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Microtia

Drugs mentioned

• AUR-201

Snippet

Sponsor: Auregen Biotherapeutics, SA | Conditions: Microtia | Phase 1, Phase 2 | Status: TERMINATED